Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Target Price at $35.40

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has been given an average rating of “Buy” by the seven brokerages that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $35.40.

LENZ has been the topic of a number of recent analyst reports. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright started coverage on LENZ Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $38.00 price target for the company. Raymond James began coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective on the stock. Finally, Piper Sandler reissued an “overweight” rating and set a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LENZ. American International Group Inc. acquired a new position in shares of LENZ Therapeutics during the 1st quarter worth about $44,000. SG Americas Securities LLC acquired a new position in shares of LENZ Therapeutics during the 3rd quarter worth approximately $107,000. Marquette Asset Management LLC acquired a new position in shares of LENZ Therapeutics during the 1st quarter worth approximately $131,000. Squarepoint Ops LLC acquired a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. Finally, Rhumbline Advisers boosted its holdings in shares of LENZ Therapeutics by 265.6% in the 2nd quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock valued at $291,000 after buying an additional 12,214 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

NASDAQ:LENZ opened at $27.93 on Friday. LENZ Therapeutics has a 1-year low of $14.07 and a 1-year high of $31.00. The business’s 50-day moving average price is $24.03 and its two-hundred day moving average price is $20.71.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. Analysts predict that LENZ Therapeutics will post -3.15 earnings per share for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.